← Back to Clinical Trials
Recruiting NCT06597617

NCT06597617 Persistent Organic Pollutants and Mechanical Discharge: Limiting the Impact of Bariatric Surgery Through Personalized Adapted Physical Activity

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06597617
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Nice
Condition Obesity
Study Type INTERVENTIONAL
Enrollment 60 participants
Start Date 2025-06
Primary Completion 2028-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 55 Years
Study Type INTERVENTIONAL
Interventions
Adapted physical activity with aerobic training [GEA]Adapted physical activity with strength training [GRM]

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 60 participants in total. It began in 2025-06 with a primary completion date of 2028-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

For the most severe cases of obesity, recourse to bariatric surgery is the ultimate solution. Although highly beneficial to individual health, this massive loss of body mass could also have negative effects on metabolism and neuromuscular function. Unfortunately, these effects have been relatively little studied in the scientific literature, and are poorly taken into account in patient follow-up when bariatric surgery has been recommended. One of the adverse effects of bariatric surgery is the release into the bloodstream of Persistent Organic Pollutants (POPs) which, are not only persistent, but also bioaccumulative, toxic and mobile. The major problem is that these circulating POPs are linked to a number of adverse side effects, including reproductive disorders, neurobehavioral alterations, metabolic disorders, gut microbiota alterations inflammatory changes and physiological alterations. POP neurotoxicity could also affect psychomotor abilities and neuromuscular function. In addition, the mechanical unloading (i.e., reduced mechanical stress on muscles) induced by loss of body mass, an effect targeted by bariatric surgery and largely beneficial to the health of individuals, could also alter neuromuscular function and potentially alter muscle architecture and contractile properties. Unfortunately, no data are currently available in the scientific literature to confirm or refute these hypotheses. Physical activity-based intervention strategies may be usefull to counteract the effects of mechanical unloading and the release of POPs as suggested in scientific literature. However it is also possible to question which exercise modality should be preferred. Our hypothesis is that eccentric muscle strengthening would better preserve muscle mass and neuromuscular function while limiting the risks associated with POPs release, compared with an aerobic and a control group.

Eligibility Criteria

Inclusion Criteria: * Adult patient (18-55 years) * Patient scheduled for bariatric surgery * Patient practicing a leisure-time physical activity \< 8 hours of moderate intensity per week or \< 4 hours of high intensity per week * Presence of effective contraception (hormonal or mechanical) Exclusion Criteria: * Patient already involved in another experimental study * Pregnant (urine pregnancy test) or breast-feeding women * Patient in a particular situation deemed incompatible with the study by the investigator * Patients from outside the Alpes-Maritimes and Var departments * Patient having received antibiotic treatment during the 3 months preceding the first stool collection * Presence of a contraindication to adapted physical activity * Presence of a contraindication to neurostimulation

Contact & Investigator

Central Contact

Nicolas CHEVALIER, Pr

✉ chevalier.n@chu-nice.fr

📞 04 92 03 67 55

Principal Investigator

Nicolas CHEVALIER, Pr

PRINCIPAL INVESTIGATOR

Centre Hospitalier Universitaire de Nice

Frequently Asked Questions

Who can join the NCT06597617 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Obesity. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06597617 currently recruiting?

Yes, NCT06597617 is actively recruiting participants. Contact the research team at chevalier.n@chu-nice.fr for enrollment information.

Where is the NCT06597617 trial being conducted?

This trial is being conducted at Nice, France.

Who is sponsoring the NCT06597617 clinical trial?

NCT06597617 is sponsored by Centre Hospitalier Universitaire de Nice. The principal investigator is Nicolas CHEVALIER, Pr at Centre Hospitalier Universitaire de Nice. The trial plans to enroll 60 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology